Development and Validation of Blood Tumor Mutational Burden Reference Standards Free White Paper

Request Your Free White Paper Now:

"Development and Validation of Blood Tumor Mutational Burden Reference Standards"

Free White Paper: "Development and Validation of Blood Tumor Mutational Burden Reference Standards"

Tumor mutational burden, as measured by exome or panel sequencing of tumor tissue (tTMB) or blood (bTMB), has been identified as a potential predictive biomarker for treatment benefit in patients with various cancer types receiving immunotherapy targeting checkpoint pathways (e.g. PD 1, PD L1, CTLA 4). However, significant variability in TMB measurement has been reported due to differences in pre-analytical and laboratory methods, panel size, number of genes covered, and bioinformatics pipelines
View full description >

Get Started

Complete the form below:

Work Email Address

First Name

Last Name

Company Name

Job Title

Job Area

Please Specify
for Other:

Work Phone Number

Company Size

Company Industry

Please Specify
for Other:

Company Street Address

Company Suite/Office

Company Postal/Zip Code

Company City

Company State

Company Country

Summary

Valid email address is required to fulfill your request.

To learn more about how your data is processed, stored, and kept secure please read our Privacy Policy.

	Pharmaceutical/Biopharmaceutical Company	Ag-Bio Company
	Contract Research Organization	Genomic Services Provider
	Diagnostic Developer	Instrument Manufacturer/Vendor
	Core Lab	Academic/University/Nonprofit Research Institute
	Government Agency	CLIA Lab: Hospital
	CLIA Lab: Independent	CLIA Lab: Physician/Group Practice
	Hospital/Medical Center	Private/Group Medical Practice
	Management Consultant/Venture Capital/Law Firm	Public Relations/Advertising Firm

Request Your Free White Paper Now: